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Abstract
Objective: There are no long-term medical treatments for uterine fibroids, and non-invasive biomarkers are needed to
evaluate novel therapeutic interventions. The aim of this study was to determine whether serial dynamic contrast-enhanced
MRI (DCE-MRI) and magnetization transfer MRI (MT-MRI) are able to detect changes that accompany volume reduction in
patients administered GnRH analogue drugs, a treatment which is known to reduce fibroid volume and perfusion. Our
secondary aim was to determine whether rapid suppression of ovarian activity by combining GnRH agonist and antagonist
therapies results in faster volume reduction.
Methods: Forty women were assessed for eligibility at gynaecology clinics in the region, of whom thirty premenopausal
women scheduled for hysterectomy due to symptomatic fibroids were randomized to three groups, receiving (1) GnRH
agonist (Goserelin), (2) GnRH agonist+GnRH antagonist (Goserelin and Cetrorelix) or (3) no treatment. Patients were
monitored by serial structural, DCE-MRI and MT-MRI, as well as by ultrasound and serum oestradiol concentration
measurements from enrolment to hysterectomy (approximately 3 months).
Results: A volumetric treatment effect assessed by structural MRI occurred by day 14 of treatment (9% median reduction
versus 9% increase in untreated women; P = 0.022) and persisted throughout. Reduced fibroid perfusion and permeability
assessed by DCE-MRI occurred later and was demonstrable by 2–3 months (43% median reduction versus 20% increase
respectively; P = 0.0093). There was no apparent treatment effect by MT-MRI. Effective suppression of oestradiol was
associated with early volume reduction at days 14 (P = 0.041) and 28 (P = 0.0061).
Conclusion: DCE-MRI is sensitive to the vascular changes thought to accompany successful GnRH analogue treatment of
uterine fibroids and should be considered for use in future mechanism/efficacy studies of proposed fibroid drug therapies.
GnRH antagonist administration does not appear to accelerate volume reduction, though our data do support the role of
oestradiol suppression in GnRH analogue treatment of fibroids.
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Introduction
Uterine fibroids (leiomyomas) are present in up to 70% of
women of reproductive age [1], many of whom report significant
symptoms [2]. The burden of symptomatic fibroids has a major
impact on health care use and costs [3], with a significant number
of women in the USA reported to have had a hysterectomy for
fibroids [2], costing over $2 billion annually [4].
Surgery is the mainstay of the clinical management of
symptomatic fibroids but has inherent risks. Medical therapies
for improving heavy menstrual bleeding associated with fibroids
do not improve symptoms associated with increased uterine
volume. Gonadotrophin-releasing hormone (GnRH) agonists are
effective at reducing fibroid size [5] but are only licensed for short-
term use. There is therefore an unmet clinical need for
pharmacologic agents that alleviate all fibroid symptoms, thereby
avoiding or delaying surgery, especially in women wishing to
preserve fertility. However, in order to assess potential novel
interventions, we need sensitive imaging approaches that can
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accurately identify changes in tissue volume, vascular properties
and composition as surrogate biomarkers of therapeutic efficacy.
Against this background, our study aimed to compare serial
magnetic resonance imaging (MRI) approaches in monitoring and
predicting response to GnRH analogue, a treatment which is
expected to cause reductions in fibroid volume and perfusion. We
used T2-weighted (T2W) MRI for estimation of uterine and
fibroid volume, dynamic contrast-enhanced MRI (DCE-MRI) for
assessment of tissue perfusion and permeability, and magnetization
transfer MRI (MT-MRI) to assess changes in fibrosis and
macromolecular content. While these approaches have been
explored extensively in other organs (e.g. [6,7]), there has been
very limited application of DCE-MRI and MT-MRI in the
assessment of the fibroid uterus. Our secondary aim was to assess
whether the treatment response depends upon the oestrogenic
state of subjects. To this end, some of the treated participants
received a GnRH antagonist prior to receiving the agonist, in
order to induce hypo-oestrogenism more rapidly during the first
1–2 weeks of the study.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. Following approval from the Lothian Research and
Ethics Committee (LREC 08/MRE00/30), premenopausal women
scheduled for hysterectomy due to symptomatic fibroids were
recruited from gynaecology clinics in NHS Lothian, Scotland from
April 2009 until April 2010. The presence of benign fibroids was
confirmed histologically on hysterectomy specimens. Participants
were required to have at least one non-pedunculated fibroid
(diameter $2 cm) or multiple small fibroids (total uterine volume
$200 cm3) confirmed by pelvic ultrasound. Patients with contra-
indications to MRI or to the study drugs were excluded. Subjects
using hormonal preparations or tranexamic acid for symptom
control were able to continue taking these throughout the study
period. All participants provided written informed consent.
Study design
This was a prospective randomized open-label blind end-point
(PROBE) investigational study (http://www.clinicaltrials.gov;
NCT00746031). At screening, menstrual, medical, family and
drug histories were taken, and blood pressure, body mass index
(BMI) and urine were assessed (including human chorionic
gonadotropin to exclude pregnancy) as well as blood clinical
haematological and biochemical profiles.
Thirty participants were randomized into one of three groups
(n = 10 per group). Treatment allocation was assigned by codes in
sealed consecutively numbered opaque envelopes provided by an
independent statistician. Group 1 patients received 3 doses of a
3.6 mg subcutaneous implant of the GnRH agonist, (Goserelin) on
days 1, 28 and 56 (63 days); Group 2 patients received 3 doses of a
3 mg subcutaneous injection of the GnRH antagonist (Cetrorelix)
on days 1, 4 and 7 (61 day) followed by 3 doses of a 3.6 mg
subcutaneous implant of Goserelin on days 7, 35 and 63 (63 days);
Group 3 received no treatment. Day 1 occurred within the first 5
days of the menstrual cycle. Hysterectomy was performed 21–28
days from last dose of GnRH agonist or on day 77–84 for
untreated subjects. Neither subjects nor clinical personnel were
blinded to treatment allocation. Throughout the study, partici-
pants were monitored for adverse events with standard laboratory
safety measures.
Magnetic Resonance Imaging
MRI was acquired using a Siemens Avanto 1.5 tesla clinical
scanner using body matrix and spine coil elements (receive) and a
body coil (transmit). Scans were performed at baseline, on day 14
(63 days), on day 28 (63 days) and within 10 days of scheduled
hysterectomy. To reduce bowel motion artefact, subjects received
intravenous (oral when venous access was not available) hyoscine
20 mg (Buscopan; Boehringer Ingelheim, Germany) prior to
scanning.
T2W MRI scans (TR/TE=4470–8480/84–104 ms, slice
thickness/spacing = 4/5 mm, field of view (FoV) = 2506250 mm,
matrix size = 3206320, 2 signal averages) were acquired in the
sagittal and axial-oblique (orthogonal to the uterine lumen) planes
(Figure 1a–b) using a fast spin-echo (FSE) pulse sequence. Anterior
saturation was applied to reduce respiratory motion artefact and
the number of slices was adjusted to obtain full coverage of the
uterus.
MT-MRI was acquired in the sagittal plane using a FSE
sequence (TR/TE=797/11 ms, 44 contiguous 3 mm slices,
FoV=3006300 mm, matrix size = 1926192, 2 signal averages
(Figure 1c). Magnetization transfer pulses with bandwidth 250 Hz,
flip angle 500u and duration 7680 ms were applied with a
1500 Hz-offset from the water resonance frequency. An identical
scan was performed without MT pulses.
DCE-MRI with fat suppression (Figure 1d) was acquired in the
sagittal plane using a three-dimensional T1-weighted spoiled
gradient echo sequence (44 contiguous 3 mm slices, TR/
TE=4.98/1.85 ms, flip angle = 10u, FoV=3006300 mm, matrix
size = 1926192). After the baseline scan, 15 mL gadoteric acid
(0.5 mmol/mL; DOTAREM, Guerbet, France) was injected
intravenously (Medrad Spectris Solaris EP; http://www.medrad.
com) at 3 mL/s and flushed with 0.9% saline. Starting from the
time of injection, images were acquired at 15 s intervals; after a
total of 12 acquisitions, the interval was increased to 75 s. Pre-
contrast T2W FSE scans (TR/TE=8410/84 ms) with the same
slice locations as DCE-MRI were acquired to facilitate accurate
ROI placement.
Figure 1. Sagittal (a) and axial-oblique (b) T2-weighted images showing dimensions of a large fibroid. (c) Magnetization transfer-
weighted and (d) dynamic contrast-enhanced MRI (DCE-MRI) image (acquired one minute after injection of contrast) of the same patient.
doi:10.1371/journal.pone.0089809.g001
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Image analysis
Uterine and largest fibroid volumes were the primary outcomes of the
study. To estimate uterine volume, measurements were taken from
sagittal T2W images from the internal cervical os to the most
distant point of the uterus, and of the longest axis perpendicular to
this; a third left-right measurement was made using axial-oblique
images. To estimate fibroid volume, orthogonal long- and short-
axis measurements of the largest fibroid were taken in the sagittal
view (Figure 1a), together with a left-right measurement in the
axial-oblique view (Figure 1b). For both structures, the three
orthogonal distances Li were combined using the equation for the
volume of an ellipsoid (V= p/66L16L26L3). Measurements were
made by consensus of two readers (KM and MT) and verified by
an experienced radiologist (GM).
DCE-MRI. Regions of interest (ROIs) encompassing the
largest fibroid were drawn on sagittal T2W images and used to
generate averaged DCE-MRI signal intensity curves. For assess-
ment of contrast uptake in the myometrium at baseline, three
circular ROIs (diameter #8 mm) were drawn in a region of
normal-appearing myometrium and the signals from these were
combined to generate averaged signal intensity curves. All curves
were fitted using the kinetic model of Brix and co-workers [8,9]
Figure 2. CONSORT flow diagram showing enrolment and progress of study participants.
doi:10.1371/journal.pone.0089809.g002
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using software written in Matlab (MathWorks, Inc., Natick, MA,
USA).
S(t){S(0)
S(0)
~A
e{kep(t{t0){e{kel (t{t0)
kel{kep
 
,
where S(0) and S(t) represent the signal intensity at baseline and
time t respectively, A is a constant of proportionality, t0 accounts
for the unknown arrival time of the contrast agent in the tissue, kel
is the rate constant for the removal of contrast and kep is the rate
constant for transfer of contrast from the extracellular extravas-
cular space to the blood pool. Example data with fitting to this
model are shown in Figure S1.
MT-MRI. The fibroid tissue ROIs described above were
transferred to the MT-MRI images and averaged magnetization
transfer ratio (MTR) values were calculated as 1006(S22S+)/S2,
where S+ and S2 are the ROI-averaged signal intensities in the
MT-weighted and non-MT-weighted images respectively.
Ovarian activity
Blood samples for circulating serum oestradiol concentrations
were collected on days 1, 4, 7 and 1161 day, at imaging visits 63
days and on the day of hysterectomy. Serum oestradiol was
measured using the ARCHITECT assay (Abbott Diagnostics,
Maidenhead, UK) that utilises Chemiluminescent Microparticle
Immunoassay (CMIA) technology; the analytical sensitivity was
#10 pg/mL.
Sonographic assessment
Ultrasound was performed at the screening visit to identify the
location and size of the largest fibroid and subsequently on the
same dates as MRI 63 days. All ultrasound scans were performed
transabdominally and, in most cases, transvaginally; volumes were
calculated using the latter where image quality permitted. Three
measurements of the uterus and largest fibroid were recorded
(longitudinal, transverse and anterior-posterior) and volumes were
calculated using the ellipsoid equation as above. The position of
the largest fibroid was noted to ensure assessment of the same
fibroid at each visit. Colour Doppler imaging was carried out at all
visits, with impedance to uterine blood flow distal to the point of
sampling estimated using the pulsatility index (PI), defined as
systolic minus end diastolic peak velocity divided by time-averaged
maximum velocity [10]. Three measurements were taken from
each of the left and right uterine arteries; the mean value was
calculated for each side and the two sides were then averaged. All
scans were performed using the same Siemens Antares machine.
The majority of the scans (79%) were carried out by one
radiologist (JW), with the remainder performed by a second
radiologist (TF).
Table 1. Patient demographics: race, age, parity and BMI distribution across the treatment groups.
Treatment Group
Variable Group 1 (n =10) Group 2 (n =10) Group 3 (n=10) All subjects (n =30)
Race, n (%) Black 1 (10) 0 (0) 0 (0) 1 (3.3)
Caucasian 9 (90) 10 (100) 10 (100) 29 (96.7)
Age, years Mean 45.4 45.9 46 45.8
Min, Max 40, 52 42, 53 42, 52 40, 53
Parity, n (%) Nulliparous 3 (30) 5 (50) 4 (40) 12 (40)
Parous 7 (70) 5 (50) 6 (60) 18 (60)
BMI, kg/m2 Mean 30.1 28.6 32.0 30.2
Min, Max 19, 43 21, 39.5 22.1, 37.2 19, 43
doi:10.1371/journal.pone.0089809.t001
Figure 3. Box and whisker plot showing blood oestradiol concentration, with groups 1, 2 and 3 displayed in black, red and blue
respectively. * indicates samples taken on MRI scan days.
doi:10.1371/journal.pone.0089809.g003
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Statistical methods
MRI, hormone and ultrasound parameters were compared
using the Mann-Whitney U-test, while correlations between
continuous variables were assessed by Spearman rank correlation
analysis. Variables were considered statistically significant using
two-sided P,0.05. Treatment response by structural, DCE-MRI
and MT-MRI was assessed at each time point using the first (pre-
treatment) scan as the baseline. This was a hypothesis-generating
study, so no formal adjustment for multiple testing has been used.
Results
Patient demographics and recruitment
Forty patients were assessed for participation, of whom nine did
not meet the inclusion criteria and one did not attend the
screening appointment. The remaining thirty women were
randomized into one of three groups and all completed the study
to the endpoint of hysterectomy (Figure 2). One patient in Group 1
declined the third dose of GnRH agonist due to problematic heavy
menstrual bleeding. MRI scans took place on days 225 to +1
(median 26, interquartile range 8), days 13 to 18 (median 15,
interquartile range 2), days 25 to 33 (median 29, interquartile
range 1) and days 48 to 100 (median 77, interquartile range 3)
respectively.
The groups were well matched for age, ethnic origin, parity and
BMI (Table 1). No patient developed withdrawal criteria during
the study, nor received the incorrect treatment. Adverse events are
described in (Text S1 and Table S1). This was a hypothesis-
generating study: adjustment for multiple testing was not used for
calculating the exploratory P-values presented below.
Ovarian activity
Serum oestradiol concentrations for the three groups are shown
in Figure 3. At baseline (day 1), the concentrations in the groups
were similar. At day 4, serum oestradiol concentrations were
raised in Group 1 compared with Group 2 (P=0.040), consistent
with suppression of the oestradiol ‘‘flare’’ by the GnRH
antagonist. However, no subsequent differences in serum oestra-
diol concentrations were observed between the two treated groups,
indicating little difference in ovarian activity. Since the treatment
regimes of Groups 1 and 2 were similar (GnRH agonist only) after
the first week, these subjects were combined into a single treatment
group for analysis of imaging data. Treated subjects displayed
reduced serum oestradiol concentrations relative to untreated
women at days 7 (P=0.0018), 11 (P=0.052), and at second (day
14; P=0.023), third (day 28; P,0.001) and final (2–3 months;
P,0.001) imaging visits.
Volume (T2W-MRI and ultrasound)
Baseline volumes (Table 2) measured by MRI were similar
among treated and untreated participants. Reductions in uterine
and fibroid volume among all treated patients (groups 1 and 2
combined) compared with untreated patients (group 3) were
observed at day 14, and the size of this treatment effect increased
throughout the study. Median reductions in uterine (fibroid) volume
among treated patients were 9.1 (7.7) %, 16.6 (16.7) % and 39.0
(25.3) % at day 14, day 28 and 2–3 months respectively (Figure 4,
Table 2); there were no substantial changes in the fibroid and
uterine volumes for the untreated group, and the response of groups
1 and 2 did not differ significantly at any of the time points. Initial
volume was not associated with final percentage volume change in
patients receiving treatment for either uterus (rs=0.093, P=0.70) or
fibroid (rs=20.12, P=0.62). Ultrasound measurements showed
similar volume changes (Figure S2) but a significant treatment effect
was not identifiable until the final measurement.
Perfusion and permeability (DCE-MRI and Doppler
Ultrasound)
Changes in the contrast uptake properties of the largest fibroid
(assessed by DCE-MRI parameter kep) are shown in Figure 5 and
Table 2. In agreement with the observed volume changes, a
reduction was seen among the combined treated patients (groups 1
and 2) relative to untreated patients (group 3). However, this was
apparent only at the final measurement (2–3 months), with a
42.7% median reduction in treated patients compared with a
20.1% increase for untreated participants (P=0.0093). In contrast
to volumetric assessment, no treatment effect was observed at
earlier measurements. The treatment response for groups 1 and 2
did not differ significantly at any of the follow-up scans. Baseline
Table 2. MRI parameters at baseline and follow-up scans: uterine and fibroid volume, kep (DCE-MRI) and magnetization transfer
ratio.
Treated Untreated
Variable Baseline day 14 day 28 2–3 months Baseline day 14 day 28 2–3 months
uterine volume (ml)median 555.2 440.5 468.0 351.1 556.9 478.5 484.3 500.8
min 119.4 83.8 80.6 55.7 201.1 233.0 176.8 261.3
max 1990.3 1885.5 1367.7 1326.5 1003.7 1019.6 1114.6 1044.1
fibroid volume (ml) median 249.6 223.3 181.4 145.7 127.7 141.7 141.2 131.9
min 2.4 1.9 2.4 1.8 29.3 34.0 23.3 41.1
max 1179.6 1053.5 713.5 739.8 490.7 723.2 591.6 669.8
DCE-MRI (kep/s
21) median 0.0854 0.0507 0.0591 0.0389 0.0492 0.0734 0.0748 0.0931
min 0.0201 0.0241 0.0153 0.0169 0.0279 0.0242 0.0160 0.0275
max 0.2123 0.1818 0.1956 0.1364 0.1529 0.1028 0.1684 0.1220
MTR (%) median 12.0 11.7 13.0 12.4 12.2 11.3 12.8 12.2
min 10.1 6.8 9.7 7.5 6.6 5.7 5.0 6.1
max 20.3 18.5 15.9 18.9 15.3 15.4 17.1 16.1
doi:10.1371/journal.pone.0089809.t002
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myometrium (though not fibroid) kep was associated with final
uterine volume change for treated patients (rs=20.57;
P=0.0099). Myometrium (though not fibroid) kep was also
negatively associated with uterine (rs =20.38; P=0.049) and
fibroid (rs=20.51; P=0.0063) volume among all patients at
baseline.
Doppler ultrasound assessment of the uterine arteries (Figure 5b)
showed complementary increases in PI in treated versus untreated
patients at day 28 (P=0.030) and at 2–3 months (P=0.0016).
However, pre-treatment Doppler ultrasound did not predict final
uterine volume change in treated patients (rs=0.10, P=0.67).
Fibroid composition (MT-MRI)
In contrast to the observed volumetric response, serial MT-MRI
revealed no differences in response between treated and untreated
patients (or between the two treated groups) at any of the follow-up
scans (Table 2, Table S2). Baseline MTR was not associated with
final uterine volume change, although baseline MTR was
negatively associated with initial uterine (rs =20.46; P=0.011)
and fibroid (rs =20.52; P=0.0036) volume.
Hypo-oestrogenism and treatment effect
As discussed above, there were no differences in serum
oestradiol concentrations after day 4 between those patients
receiving an initial regime of GnRH antagonist followed by
GnRH agonist, and those receiving only GnRH agonist.
Consistent with this, we found no differences between these two
groups by serial MRI. Nevertheless, there was variation in residual
serum oestradiol concentrations among treated patients. To assess
the dependence of treatment response on hypo-oestrogenism,
treated patients were dichotomised as oestradiol-suppressed
([E2]#81.5 pg/mL) or unsuppressed ([E2].81.5 pg/mL), with
the median serum oestradiol concentration at day 14 used as the
cut-off. As shown in Figure 6a, volume reduction in ‘‘suppressed’’
patients was greater than in ‘‘unsuppressed’’ patients at days 14
and 28 (statistical testing is not reported for the final scan as all but
two treated participants were oestradiol-suppressed by this time
point). Suppressed patients also showed greater reduction in kep
(Figure S3) although the differences did not reach statistical
significance; however, as illustrated in Figure 6b, volume reduction
was accompanied in most patients by hypo-oestrogenism and a
reduction in kep.
Discussion
The main objective of this study was to compare structural
MRI, DCE-MRI and MT-MRI as potential biomarkers of
response to fibroid drug treatment. We found that structural
MRI was able to identify a significant volumetric treatment effect
as early as day 14 following commencement of treatment, and at
the following two scans. This effect was detected by standard
clinical ultrasound only 2–3 months after commencement of
treatment. These data support the use of structural MRI as the
preferred technique for detecting early volumetric treatment
response and, as far as we are aware, represent the earliest
detected volumetric reduction of a GnRH analogue treatment.
These data also show for the first time that the change in fibroid
volume with GnRH analogue treatment is rapid. The magnitude
of the volume changes were comparable to those found in previous
studies utilising GnRH agonist therapy [11,12]. Just as fibroid
growth rates have been shown not to be influenced by tumour size
[13], we found that fibroid and uterine size did not predict final
percentage volume change in treated patients.
Perfusion and permeability
Assessment of fibroid change in response to treatment by DCE-
MRI showed a treatment effect at 2–3 months, complementary to
but much later than volumetric changes detected by structural
MRI. Treatment may reduce the uterine blood supply in the early
stages (as demonstrated by our Doppler ultrasound findings and
those of previous investigators [14]), but without affecting the
fibroid ‘core’ until later in the treatment cycle, when uterine blood
Figure 4. Median % volume change of (a) uterus and (b) largest
fibroid from baseline at day 14, day 28 and 2 to 3 months (i.e.
within 10 days of hysterectomy), measured by T2-weighted
MRI; error bars show the interquartile range. Figure shows data
for treated (groups 1 and 2) and untreated participants.
doi:10.1371/journal.pone.0089809.g004
Figure 5. Changes in uterine vascular properties at day 14, day
28 and 2 to 3 months (i.e. within 10 days of hysterectomy). (a)
Shows median % change in the fibroid dynamic contrast-enhanced MRI
(DCE-MRI) parameter kep from baseline, while (b) shows corresponding
changes in pulsatility index (PI) as measured by Doppler ultrasound of
the uterine arteries. Error bars show the interquartile range. Figure
shows data for treated (groups 1 and 2) and untreated participants.
doi:10.1371/journal.pone.0089809.g005
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flow has fallen sufficiently to limit the uptake of contrast. Since we
assessed averaged contrast uptake across the whole fibroid, such
local variations in the treatment effect may be obscured.
Furthermore, caution should be exercised in interpreting changes
in contrast uptake, which is influenced by multiple properties
including blood flow, vascular permeability and the extracellular
volume. Shimada et al have previously demonstrated a positive
association between fibroid vessel density and MRI contrast
enhancement [15]. Further work using DCE-MRI with higher
temporal resolution and arterial concentration measurement
should allow some of these factors to be disentangled [16].
Pre-treatment DCE-MRI of myometrium was negatively
associated with the final uterine volume change. It is unclear
whether this reflects greater availability of the pharmacologic
agent, or simply that a highly perfused uterus is more strongly
affected by reductions in blood supply. A previous study using
qualitative contrast-enhanced MRI has suggested that enhancing
fibroids show greater volume reduction than unenhanced fibroids
[17]. Whilst this may reflect a reduced treatment response in
poorly-enhanced hyalinised fibroids [18,19], we did not find pre-
treatment fibroid kep to be associated with final volume change.
Qualitative contrast-enhanced MRI is used clinically to assess
suitability for uterine artery embolisation treatment and to
demonstrate the consequent reductions in perfusion [20]. As far
as we are aware, this is the first study in which quantitative DCE-
MRI has been employed in patients with fibroids who have been
administered GnRH agonist therapy. We have shown that DCE-
MRI is sensitive to therapy-induced vascular changes in fibroid
tissue and as such it may be useful in future studies of therapeutic
efficacy and mechanism. Nevertheless, it will be necessary to
balance the acquisition of additional scientific information against
the cost of administering contrast agent and increasing the total
duration of the imaging protocol.
Fibroid composition (MT-MRI)
Whilst MT-MRI has been reported in relation to other uterine
pathology [21], MT-MRI has not previously been used to assess
uterine fibroids, except as an incidental finding during whole body
MRI [22]. Here, we were unable to identify a treatment effect by
MT-MRI during the study. A possible reason is that GnRH
therapy does not substantially alter the fibroid tissue structure on a
2–3 month timescale. Moreover, long acquisition times at 1.5T
limited the accuracy of MTR measurement in the presence of
patient motion. We have recently piloted faster MT-MRI
acquisition at 3T and this permits rapid voxel-based MTR
mapping that may enhance the sensitivity of this technique.
Dependence on hypo-oestrogenism
As expected, initial treatment with GnRH antagonist preceding
GnRH agonist therapy resulted in lower serum oestradiol
concentrations on day 4. We found greater uterine volume
reduction in treated patients with the lowest serum oestradiol
concentrations as early as day 14, implying that rapid suppression
of ovarian activity is related to early volume reduction. Similar
effects were seen by DCE-MRI. It has previously been demon-
strated that uterine fibroids are hormone-dependent, with
reductions in oestradiol (e.g. following the menopause) causing
Figure 6. Relationship between oestradiol concentration, and volumetric and vascular changes. (a) shows median uterine volume
change, assessed by T2-weighted MRI; error bars show the interquartile range. Data are shown for treated participants (groups 1 and 2), classified as
oestradiol-suppressed and -unsuppressed as described in the text. (b) shows changes in uterine volume and fibroid kep (DCE-MRI) for all patients
(group 1: black, group 2: red, group 3: blue) at the final MRI scan. The areas of the data points are proportional to blood oestradiol concentration at
the same time point (the largest data point corresponds to a value of 1153 pg/mL).
doi:10.1371/journal.pone.0089809.g006
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fibroids to decrease in size [23,24]. While the underlying
mechanism of GnRH analogue-induced fibroid reduction is not
well-understood [25], recent work by Khan et al [26] found that
GnRH agonists reduced the inflammatory reaction, angiogenesis
and micro-vessel density and induced apoptosis in uterine fibroids.
Our data support the hypothesis that shrinkage is caused by
suppression of ovarian activity and mediated by a reduction in
perfusion.
Conclusions
These data demonstrate that structural MRI can detect small,
early responses to treatment prior to detection by standard clinical
ultrasound. DCE-MRI allows the measurement of a vascular
treatment response in fibroid tissue complementary to structural
changes following 2–3 months of treatment and may also be a
predictor of treatment response. Our data would suggest that MRI
should be considered an important imaging modality for
assessment of response to novel therapeutic interventions for this
important and potentially debilitating condition.
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Figure S1 Example DCE-MRI data showing signal
enhancement vs. time with fitting to the kinetic model
described in the Materials and Methods section. Data
from four serial scans from the same treated patient are displayed,
showing reduction in the perfusion and permeability parameter
kep.
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Figure S2 Median % volume change of (a) uterus and
(b) largest fibroid from baseline at day 14, day 28 and 2
to 3 months (i.e. within 10 days of hysterectomy),
measured by ultrasound; error bars show the inter-
quartile range. Figure shows data for treated and untreated
participants.
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Figure S3 Median kep change, assessed by DCE-MRI;
error bars show the interquartile range. Figure shows data
for treated participants, classified as oestradiol-suppressed and -
unsuppressed as described in the text.
(TIF)
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